HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TheraVida Inc.

www.theravida.com

Latest From TheraVida Inc.

Deal Watch: Allogene Gets Pfizer's Off-The-Shelf CAR-T Program, $300m Series A Backing

Celgene reworks its collaboration with Abide, dropping its buyout option. Roivant gains Chinese rights to anti-infective lemafulin and adds a fifth candidate to Dermavant's pipeline, while pSivida acquires Icon and FDA-approved Dexycu for cataract surgery inflammation.
Deals Business Strategies

Deals Shaping The Medical Industry, June 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Livin' TheraVida loca: Tolenix and follow-on licensed to Korea's SK

The news in a nutshell

Gynecology & Urology

TheraVida to conduct more studies of Tolenix after reporting positive Phase II data

TheraVida said it intends to conduct additional international clinical trials of its lead product candidate, Tolenix (THVD-201), for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI) having reported positive Phase II data for the drug.

Gynecology & Urology New Zealand
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • TheraVida Inc.
  • Senior Management
  • Mehdi Paborji, PhD, Pres. & COO
    Kenneth Duchin, PhD, VP, Preclinical & Clinical Dev.
  • Contact Info
  • TheraVida Inc.
    Phone: (650) 903-2225
    800 West El Camino Real
    Suite 180
    Mountain View, CA 94040
    USA
UsernamePublicRestriction

Register